Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Liming Wu

Showing results (331-340 of 343) with videos related to

Pageof 35
Sort By:
Dermatitis : Contact, Atopic, Occupational, Drug|March 28, 2025
Long-Term Stapokibart Treatment Induces Sustained Clinical Improvements in Patients With Moderate-to-Severe Atopic DermatitisYan Zhao, Litao Zhang, Liming Wu, et al.
International Journal of Dermatology|November 22, 2025
Efficacy and Safety of Anti-IL-4Rα Stapokibart in Elderly Patients With Moderate-To-Severe Atopic DermatitisYan Zhao, Litao Zhang, Liming Wu, et al.
Advances in Therapy|July 12, 2025
Patient-Reported Outcomes in Adults with Moderate-to-Severe Atopic Dermatitis Treated with Stapokibart over 52 weeks: A Post Hoc Analysis of a Phase 3 TrialYan Zhao, Litao Zhang, Liming Wu, et al.
Clinical and Translational Allergy|November 19, 2025
Efficacy and Safety of Stapokibart in Adults With Moderate-to-Severe Atopic Dermatitis With and Without Type 2 Comorbidities: A Post Hoc Analysis of a Phase 3 TrialYan Zhao, Litao Zhang, Liming Wu, et al.
The Journal of Dermatological Treatment|July 6, 2026
Stapokibart provides significant improvements in signs and symptoms of atopic dermatitis irrespective of prior systemic treatment: a post-hoc analysis of a phase 3 trialYan Zhao, Litao Zhang, Liming Wu, et al.
Dermatitis : Contact, Atopic, Occupational, Drug|November 5, 2025
MG-K10, a Long-Acting Anti-IL-4 Receptor Alpha Monoclonal Antibody in Adult Patients with Moderate-to-Severe Atopic DermatitisChaoying Gu, Litao Zhang, Yumei Li, et al.
The British Journal of Dermatology|February 16, 2026
Efficacy and safety of stapokibart in adolescents with moderate-to-severe atopic dermatitis: a multicenter, randomized, double-blind, placebo-controlled phase 3 trialCheng Zhou, Yan Zhao, Guannan Zhu, et al.
Journal of the American Academy of Dermatology|September 18, 2025
Novel TYK2 inhibitor D-2570 in moderate-to-severe plaque psoriasis: A randomized, double-blind, placebo-controlled, phase 2 trialJianzhong Zhang, Cheng Zhou, Guoying Miao, et al.
Dermatology and Therapy|May 18, 2026
Safety, Pharmacokinetics, and Efficacy of 1.5% Ruxolitinib Gel (HDM3010) in Adult Patients with Prurigo Nodularis: A Phase I/II, Randomized, Double-Blind, Vehicle-Controlled Multicenter Clinical TrialChao Wu, Xuping Niu, Xiaohua Wang, et al.
The British Journal of Dermatology|November 29, 2025
Ivarmacitinib ointment for the treatment of adults with mild-to-moderate atopic dermatitis: phase 3 part of a randomized, double-blind, placebo-controlled, phase 2/3 clinical trialDuoqin Wang, Jiyuan Wu, Qing Guo, et al.
Pageof 35

Showing results (331-340 of 343) with videos related to

Sort By:
Pageof 35
Dermatitis : Contact, Atopic, Occupational, Drug|March 28, 2025
Long-Term Stapokibart Treatment Induces Sustained Clinical Improvements in Patients With Moderate-to-Severe Atopic DermatitisYan Zhao, Litao Zhang, Liming Wu, et al.
International Journal of Dermatology|November 22, 2025
Efficacy and Safety of Anti-IL-4Rα Stapokibart in Elderly Patients With Moderate-To-Severe Atopic DermatitisYan Zhao, Litao Zhang, Liming Wu, et al.
Advances in Therapy|July 12, 2025
Patient-Reported Outcomes in Adults with Moderate-to-Severe Atopic Dermatitis Treated with Stapokibart over 52 weeks: A Post Hoc Analysis of a Phase 3 TrialYan Zhao, Litao Zhang, Liming Wu, et al.
Clinical and Translational Allergy|November 19, 2025
Efficacy and Safety of Stapokibart in Adults With Moderate-to-Severe Atopic Dermatitis With and Without Type 2 Comorbidities: A Post Hoc Analysis of a Phase 3 TrialYan Zhao, Litao Zhang, Liming Wu, et al.
The Journal of Dermatological Treatment|July 6, 2026
Stapokibart provides significant improvements in signs and symptoms of atopic dermatitis irrespective of prior systemic treatment: a post-hoc analysis of a phase 3 trialYan Zhao, Litao Zhang, Liming Wu, et al.
Dermatitis : Contact, Atopic, Occupational, Drug|November 5, 2025
MG-K10, a Long-Acting Anti-IL-4 Receptor Alpha Monoclonal Antibody in Adult Patients with Moderate-to-Severe Atopic DermatitisChaoying Gu, Litao Zhang, Yumei Li, et al.
The British Journal of Dermatology|February 16, 2026
Efficacy and safety of stapokibart in adolescents with moderate-to-severe atopic dermatitis: a multicenter, randomized, double-blind, placebo-controlled phase 3 trialCheng Zhou, Yan Zhao, Guannan Zhu, et al.
Journal of the American Academy of Dermatology|September 18, 2025
Novel TYK2 inhibitor D-2570 in moderate-to-severe plaque psoriasis: A randomized, double-blind, placebo-controlled, phase 2 trialJianzhong Zhang, Cheng Zhou, Guoying Miao, et al.
Dermatology and Therapy|May 18, 2026
Safety, Pharmacokinetics, and Efficacy of 1.5% Ruxolitinib Gel (HDM3010) in Adult Patients with Prurigo Nodularis: A Phase I/II, Randomized, Double-Blind, Vehicle-Controlled Multicenter Clinical TrialChao Wu, Xuping Niu, Xiaohua Wang, et al.
The British Journal of Dermatology|November 29, 2025
Ivarmacitinib ointment for the treatment of adults with mild-to-moderate atopic dermatitis: phase 3 part of a randomized, double-blind, placebo-controlled, phase 2/3 clinical trialDuoqin Wang, Jiyuan Wu, Qing Guo, et al.
Pageof 35